To further evaluate its impact on drug sensitivity in ovarian cancer cells, we screened a collection of 180 small-molecule inhibitors (Supplementary Data 2) targeting wide-ranging signaling pathways using MCL1-depleted SW-1573 cells (Supplementary Fig. 6a). Here, MCL1 is linked to ovarian carcinoma.